Oncompass Medicine

Executive Summary

Oncompass Medicine is a Hungarian precision oncology company founded in 2014 that leverages artificial intelligence to power its decision support and diagnostic platform. The company’s Precision Oncology Program analyzes tumor genetics via proprietary software, delivering personalized therapy recommendations to oncologists. By bridging molecular diagnostics with AI-driven treatment planning, Oncompass aims to improve outcomes and reduce trial-and-error in cancer care. Operating as a service provider, it targets both clinicians and patients seeking data-driven, tailored treatment strategies. While still private and without disclosed funding rounds or revenue, Oncompass operates in the rapidly growing AI diagnostics space, with potential for significant impact in personalized oncology. The company’s value proposition aligns with the global shift toward precision medicine, especially as genomic testing becomes more accessible. Oncompass’s technology could differentiate itself through its integrated approach and focus on Central European markets. However, given the lack of publicly available milestones, regulatory clearances, or commercial traction, the company remains at an early stage with execution risks. A successful scale-up will depend on partnerships, clinical validation, and securing investment. Overall, Oncompass Medicine represents a promising but early-stage opportunity in AI-driven oncology diagnostics.

Upcoming Catalysts (preview)

• Q3 2026Announcement of clinical partnership with a major European cancer center60% success
• Q4 2026Receipt of CE marking or other regulatory clearance for core AI platform40% success
• TBDSeries A funding round closure or grant award50% success